S&P 500   4,240.81 (-0.77%)
DOW   33,319.09 (-0.89%)
QQQ   352.19 (-0.57%)
AAPL   169.50 (-1.43%)
MSFT   310.45 (-0.54%)
META   297.26 (-0.57%)
GOOGL   129.39 (+0.64%)
AMZN   125.17 (-0.64%)
TSLA   235.65 (-3.47%)
NVDA   418.16 (-0.23%)
NIO   8.31 (-1.19%)
BABA   85.54 (-0.43%)
AMD   96.96 (+1.04%)
T   14.81 (-1.40%)
F   12.26 (-1.37%)
MU   67.05 (-1.31%)
CGC   0.87 (-5.88%)
GE   110.50 (+0.52%)
DIS   79.32 (-0.91%)
AMC   7.70 (-2.65%)
PFE   31.91 (-1.51%)
PYPL   56.78 (-3.65%)
NFLX   377.40 (-0.49%)
S&P 500   4,240.81 (-0.77%)
DOW   33,319.09 (-0.89%)
QQQ   352.19 (-0.57%)
AAPL   169.50 (-1.43%)
MSFT   310.45 (-0.54%)
META   297.26 (-0.57%)
GOOGL   129.39 (+0.64%)
AMZN   125.17 (-0.64%)
TSLA   235.65 (-3.47%)
NVDA   418.16 (-0.23%)
NIO   8.31 (-1.19%)
BABA   85.54 (-0.43%)
AMD   96.96 (+1.04%)
T   14.81 (-1.40%)
F   12.26 (-1.37%)
MU   67.05 (-1.31%)
CGC   0.87 (-5.88%)
GE   110.50 (+0.52%)
DIS   79.32 (-0.91%)
AMC   7.70 (-2.65%)
PFE   31.91 (-1.51%)
PYPL   56.78 (-3.65%)
NFLX   377.40 (-0.49%)
S&P 500   4,240.81 (-0.77%)
DOW   33,319.09 (-0.89%)
QQQ   352.19 (-0.57%)
AAPL   169.50 (-1.43%)
MSFT   310.45 (-0.54%)
META   297.26 (-0.57%)
GOOGL   129.39 (+0.64%)
AMZN   125.17 (-0.64%)
TSLA   235.65 (-3.47%)
NVDA   418.16 (-0.23%)
NIO   8.31 (-1.19%)
BABA   85.54 (-0.43%)
AMD   96.96 (+1.04%)
T   14.81 (-1.40%)
F   12.26 (-1.37%)
MU   67.05 (-1.31%)
CGC   0.87 (-5.88%)
GE   110.50 (+0.52%)
DIS   79.32 (-0.91%)
AMC   7.70 (-2.65%)
PFE   31.91 (-1.51%)
PYPL   56.78 (-3.65%)
NFLX   377.40 (-0.49%)
S&P 500   4,240.81 (-0.77%)
DOW   33,319.09 (-0.89%)
QQQ   352.19 (-0.57%)
AAPL   169.50 (-1.43%)
MSFT   310.45 (-0.54%)
META   297.26 (-0.57%)
GOOGL   129.39 (+0.64%)
AMZN   125.17 (-0.64%)
TSLA   235.65 (-3.47%)
NVDA   418.16 (-0.23%)
NIO   8.31 (-1.19%)
BABA   85.54 (-0.43%)
AMD   96.96 (+1.04%)
T   14.81 (-1.40%)
F   12.26 (-1.37%)
MU   67.05 (-1.31%)
CGC   0.87 (-5.88%)
GE   110.50 (+0.52%)
DIS   79.32 (-0.91%)
AMC   7.70 (-2.65%)
PFE   31.91 (-1.51%)
PYPL   56.78 (-3.65%)
NFLX   377.40 (-0.49%)
NASDAQ:ENOB

Enochian Biosciences (ENOB) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.40
▼
$0.79
52-Week Range
N/A
Volume
88,300 shs
Average Volume
137,347 shs
Market Capitalization
$40.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

ENOB stock logo

About Enochian Biosciences (NASDAQ:ENOB) Stock

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.


ENOB Stock News Headlines

September 11, 2023 | barrons.com
Renovaro Biosciences Inc.
September 3, 2023 | investing.com
Renovaro Biosciences Inc (RENB)
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
August 21, 2023 | finance.yahoo.com
Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer
August 10, 2023 | finance.yahoo.com
Renovaro BioSciences, GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer
August 9, 2023 | finance.yahoo.com
AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer
July 25, 2023 | finance.yahoo.com
3 Doomed Biotech Stocks Destined for Disaster
June 23, 2023 | finanznachrichten.de
Enochian BioSciences, Inc.: Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
June 23, 2023 | finance.yahoo.com
Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
June 8, 2023 | finanznachrichten.de
Enochian BioSciences, Inc.: Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
June 8, 2023 | finance.yahoo.com
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
April 15, 2023 | markets.businessinsider.com
Grabar Law Office Investigates Claims on Behalf of Shareholders of Enochian Biosciences Inc. (ENOB)
April 3, 2023 | finance.yahoo.com
Enochian BioSciences’ CEO Letter to Shareholders
March 29, 2023 | finance.yahoo.com
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
March 13, 2023 | finanznachrichten.de
Enochian BioSciences, Inc.: Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
March 13, 2023 | msn.com
Enochian BioSciences regains Nasdaq compliance by filing pending reports
March 13, 2023 | finance.yahoo.com
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
February 23, 2023 | msn.com
Enochian gets Nasdaq listing deficiency notice for not filing 10-Q
February 23, 2023 | finance.yahoo.com
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022
January 19, 2023 | reuters.com
ENOB.O - | Stock Price & Latest News | Reuters
November 30, 2022 | seekingalpha.com
Enochian gets Nasdaq notice for delaying crucial filings
November 30, 2022 | finance.yahoo.com
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022
October 24, 2022 | finance.yahoo.com
Biotech Co-Founder, Facing Murder-for-Hire Charges, Accused of Fabricating Data
October 24, 2022 | finance.yahoo.com
Enochian BioSciences Forges Ahead With Focused Approach, Promising Future
October 21, 2022 | finance.yahoo.com
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K
October 19, 2022 | finanznachrichten.de
Enochian BioSciences, Inc.: Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform
See More Headlines
Receive ENOB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enochian Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENOB Company Calendar

Today
9/27/2023
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENOB
CUSIP
N/A
CIK
1527728
Web
www.enochianbio.com
Phone
(305) 918-1980
Fax
N/A
Employees
22
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-113,430,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-154.69%
Return on Assets
-130.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.33
Quick Ratio
0.33

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.37 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
58,280,000
Free Float
45,625,000
Market Cap
$40.80 million
Optionable
Not Optionable
Beta
1.09
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Mark R. Dybul M.D. (Age 60)
    CEO, Director & Member of HBV Scientific Advisory Board
    Comp: $950k
  • Ms. Luisa Puche (Age 59)
    CFO & Corp. Sec.
    Comp: $403.75k
  • Dr. Serhat Gümrükcü
    Co-Founder & Inventor
  • Dr. Francois Binette M.Sc. (Age 59)
    Ph.D., Chief Operating Officer
  • Mr. Greg Duczynski Ph.D.
    Sr. VP for Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ENOB Stock - Frequently Asked Questions

What other stocks do shareholders of Enochian Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enochian Biosciences investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and

What is Enochian Biosciences' stock symbol?

Enochian Biosciences trades on the NASDAQ under the ticker symbol "ENOB."

Who are Enochian Biosciences' major shareholders?

Enochian Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Houlihan Financial Resource Group Ltd. (0.35%), Goldman Sachs Group Inc. (0.20%) and State Street Corp (0.09%). Insiders that own company stock include Carl Forest Sandler and Serhat Gumrukcu.
View institutional ownership trends.

How much money does Enochian Biosciences make?

Enochian Biosciences (NASDAQ:ENOB) has a market capitalization of $0.00.

How can I contact Enochian Biosciences?

Enochian Biosciences' mailing address is 2080 Century Park EastSuite 906, Los Angeles CA, 90067. The official website for the company is www.enochianbio.com. The company can be reached via phone at (305) 918-1980 or via email at ir@enochianbio.com.

This page (NASDAQ:ENOB) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -